← All trials
NCT04971109
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Jun 30, 2023
- First posted
- Jul 21, 2021
- Last posted
- Nov 11, 2021
- Enrollment
- 445
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- SIGA TechnologiesLead sponsor
- Department of DefenseCollaborator
- SIGA TechnologiesStudy director
- Medical CBRN Defense Consortium (MCDC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.